Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Neurology, Neurosurgery & PsychiatryBiomarkers in Dementia: Clinical Utility and New Directions

Biomarkers may be used in the dementias to distinguish different aspects of the underlying pathology, detect presymptomatic pathological changes, predict decline or conversion between clinical disease states, and/or monitor disease progression and response to treatment. In this review, the authors discuss the currently available biomarkers, with a particular focus on the three most common neurodegenerative dementias: Alzheimer’s disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB).

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form